首页> 美国卫生研究院文献>Drugs - Real World Outcomes >Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease

【2h】

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease

机译：长效毒蕈碱拮抗剂与长期服用支气管扩张剂对慢性阻塞性肺疾病住院后再入院或死亡率影响的比较因果分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version of this article (10.1007/s40801-019-00171-w) contains supplementary material, which is available to authorized users.

机译：本文的在线版本（10.1007 / s40801-019-00171-w）包含补充材料，授权用户可以使用。

著录项

期刊名称 Drugs - Real World Outcomes
作者
Melissa H. Roberts; Douglas W. Mapel; Hans Petersen;
展开▼
作者单位

展开▼
年(卷),期 2020(7),1
年度 2020
页码 -1
总页数 17
原文格式 PDF
正文语种
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease [J] . Melissa H. Roberts, Douglas W. Mapel, Hans Petersen Drugs - Real World Outcomes . 2020,第1期

机译：慢性阻塞性肺病住院后长效毒蕈碱拮抗剂对慢性阻塞性肺病后入院或死亡率影响的对比因果分析
2. Cost Effectiveness of the Long-Acting P2-Adrenergic Agonist (L ABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LAB A/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal [J] . M. Reza Maleki-Yazdi, Mathieu Molimard, Dorothy L. Keininger, Applied health economics and health policy . 2016,第5期

机译：长效P2-肾上腺素激动剂（L ABA）/长效毒蕈碱拮抗药双重支气管扩张药Indacaterol / Glycopyrronium与LAB A /吸入糖皮质激素联合沙美特罗/氟替卡松在慢性阻塞性肺部疾病患者中的成本效益比较：分析法国，意大利和葡萄牙
3. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers [J] . David Singer, Lindsay GS Bengtson, Caitlin Elliott, International Journal of Chronic Obstructive Pulmonary Disease . 2020,第1期

机译：医疗保健资源利用率，慢性阻塞性肺病患者的慢性阻塞性肺病患者中的再服用，用软雾与干粉吸入器
4. Associations of Ambient Air Pollution with Chronic Obstructive Pulmonary Disease Hospitalization and Mortality [C] . Wenqi Gan, Mark Fitzgerald, Christopher Carlsten, Annual conference of the International Society of Exposure Science . 2014

机译：空气污染与慢性阻塞性肺疾病住院和死亡率的关系
5. Arrhythmia risk associated with the use of bronchodilators in patients with chronic obstructive pulmonary disease: Cohort studies and methodological issues. [D] . Wilchesky, Machelle. 2009

机译：慢性阻塞性肺疾病患者使用支气管扩张剂相关的心律失常风险：队列研究和方法学问题。
6. Healthcare Resource Utilization Exacerbations and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers [O] . David Singer, Lindsay G S Bengtson, Caitlin Elliott, 2020

机译：医疗保健资源利用率慢性阻塞性肺病患者的慢性阻塞性肺病患者中的再服用用软雾与干粉吸入器
7. Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada, France, Italy, and Portugal [O] . Maleki-Yazdi, M. Reza, Molimard, Mathieu, Keininger, Dorothy L, 2016

机译：长效β2-肾上腺素激动剂（LABA）/长效毒蕈碱拮抗剂双重支气管扩张药Indacaterol / Glycopyrronium与LABA /吸入糖皮质激素联合沙美特罗/氟替卡松在慢性阻塞性肺疾病患者中的成本效益：加拿大，法国意大利和葡萄牙

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease

摘要

著录项

相似文献

相关主题

期刊订阅